Leadership

Co-Chairs: Dawn L. Hershman, MD, MS Scott D. Ramsey, MD, PhD

Time/Location

Thursday, October 20, 2022 9:00 am - 11:00 am Room: Regency A (Ballroom Level, West Tower)

Agenda

Presentations

- Development and Testing of a Culturally Responsive Decision Aid Intervention to Promote Diversity in Clinical Trial Participation, Vida Henderson, Ph.D., Pharm.D, Fred Hutchinson Cancer Center
- Results from S1415CD, "A Pragmatic Trial To Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing, Effectiveness and Risk (TrACER)," Dr. Scott Ramsey, M.D., Ph.D., Fred Hutchinson Cancer Center
- Pragmatic Trials and Cluster Randomization Considerations, William Barlow, Ph.D., Fred Hutchinson Cancer Center

Active Studies

- S2108CD, "Randomized Comparison of an Educationally Enhanced Genomic Tumor Board (eGTB) Intervention to Usual Practice of Incorporating Genomic Test Results into Clinical Care." Dr. Jens Rueter, M.D., Maine Cancer Genomics Initiative; Dr. Meghna Trivedi, M.D, Columbia University
- <u>S1912CD</u>, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Dr. Veena Shankaran, M.D., University of Washington. Activated 7/26/21.
- <u>\$1703</u>, "Randomized Non-inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic

Hormone Receptor Positive HER-2 Breast Cancer," Dr. Melissa Accordino, M.D., Activated 7/16/18.

Developing Studies

- S2201CD, Managing Oral Anti-Cancer Agents in Community Oncology Practices: Implementation and Impact, Karen B. Farris, Ph.D., Emily Mackler, Pharm.D., University of Michigan
- Development of a Multilevel Intervention to Promote Guideline-Concordant Colorectal Cancer Surveillance – Dr. Christine Veenstra, M.D., University of Michigan
- Patient-centered Video Education Intervention to Improve Rural Cancer Care Delivery – Randall Holcombe, M.D., MBA, Izumi Okado, Ph.D., University of Hawaii

Studies with CCD/CCP Components

- <u>S1904</u>, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ

 Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)," Dr. K. Crew. Activated 9/1/20. (Committee: Prevention/ Epidemiology)
- <u>S2010</u>, Active Symptom Monitoring and Endocrine Therapy Persistence in Young Women with Breast Cancer – Lynn Henry, M.D., University of Michigan; Dawn Hershman, M.S. M.S., Columbia University

Closed Studies

- <u>S1415CD</u>, "A Pragmatic Trial To Evaluate a Guideline-Based Colony
 Stimulating Factor Standing Order Intervention and to Determine the
 Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients
 Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia
 Trial Assessing CSF Prescribing, Effectiveness and Risk (TrACER)." Drs.
 S. Ramsey, D. Hershman, G. Lyman, et al. Activated: 10/7/16. Closed:
 4/15/20.
- <u>S1417CD</u>, "Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer." Dr. V. Shankaran. Activated: 4/15/16. Closed: 2/1/19.




Substudies (Economic Analyses / Cost Effectiveness from NCTN trials)

- <u>**51806</u>**, Healthcare Cost Comparison of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle-invasive Bladder Cancer, Dr. R. Vaidya, Dr. J. Unger</u>
- S1204, A Sero-Epidemiologic Survey and Cost-effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients, Dr. R. Vaidya

Database/Grant Funded Projects

Published

- Sex Differences in Adverse Event Reporting in SWOG Chemotherapy, Biologic/Immunotherapy and Targeted Agent Cancer Clinical Trials. Dr. J. Unger
- Trends in Obesity Among Patients Registered to SWOG Cancer Clinical Treatment Trials. Dr. R. Vaidya



Email communications@swog.org to get on a list – one or all three



Accrual from trial opening through 6/30/2022 by Institution and Study

	51703	S1912CD	A191901	A231601C	A231602C	A231701C	A231901C	EAQ171CD	NHLBIMDS	NRGCC007
Ascension Prov Hospitals - Southfield	-	-	4	-	-	-	-	-	1	-
Banner U Med Ctr - Tucson	1	-	-	-	-	-	-	-	-	-
Baptist Mem HIth Care/Mid South MU NCORP	-	-	-	-	-	-	1	2	1	-
CWRU Case CCC LAPS	17	-	-	-	-	-	-	-	5	-
Ca Res Consortium of West Michigan NCORP	-	3	-	-	-	-	-	-	-	-
Ca Res for the Ozarks NCORP	-	1	-	-	-	-	-	-	-	-
Ca Res of Wisconsin & N Mich Consort	10	1	1	-	-	-	-	-	-	-
Carle CC NCORP	8	1	-	-	-	-	-	-	-	-
Columbia U MU NCORP	16	3	-	-	-	-	-	-	13	-
Columbus NCORP	4	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Inst	8	-	-	-	-	-	-	-	-	-
Cotton O'Neil CC / Stormont Vail Hlth	1	-	-	-	-	-	-	-	-	-
Dayton NCORP	3	1	-	-	-	-	-	-	-	-
Fred Hutchinson Ca Res Ctr LAPS	-	-	-	-	-	-	-	-	16	-
Georgia NCORP	2	-	-	-	-	-	-	-	-	-
Gulf South MU NCORP	б	-	-	1	-	-	-	-	-	-
Hawaii MU NCORP	б	-	-	-	-	-	-	-	5	-
Heartland Ca Res NCORP	13	4	-	-	-	-	-	-	-	1
Kaiser Permanente NCORP	4	2	-	-	-	-	-	-	5	-
Kansas City Veterans Affairs Med Ctr	-	-	-	-	-	-	-	-	4	-
Kansas Inst of Med Cancer & Blood Ctr	-	-	-	-	-	-	-	-	2	-
Lahey Hospital & Med Ctr	4	-	-	-	-	-	-	-	-	-
Loyola U Med Ctr	2	-	4	-	-	-	-	-	-	-
Massachusetts Veterans ERIC	-	-	-	-	-	-	-	-	28	-
Medical U of South Carolina MU NCORP	-	-	-	-	-	1	-	-	3	-
Michigan Ca Res Consortium NCORP	9	1	-	-	-	-	-	-	-	-



Accrual from trial opening through 6/30/2022 by Institution and Study

	51703	51912CD	A191901	A231601C	A231602C	A231701C	A231901C	EAQ171CD	NHLBIMDS	NRGCC007
Moffitt CC	-	-	-	-	-	-	-	-	8	-
Montana Cancer Consortium NCORP	7	-	-	-	-	-	-	-	-	-
MultiCare Tacoma General Hospital	-	-	21	-	-	-	-	1	-	-
NCORP Carolinas (Prisma HIth NCORP)	б	-	-	-	-	-	-	-	2	-
Nevada Ca Res Foundation NCORP	1	-	-	-	-	-	-	-	-	-
New Mexico MU NCORP	12	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	-	-	1	-
Oregon Health & Science U	-	-	-	-	-	-	-	-	9	-
Pacific Ca Res Consortium NCORP	10	2	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	4	1	-	-	-	-	-	-	-	-
UC Davis CCC LAPS	-	-	3	-	-	-	-	-	-	-
UC Irvine Health/Chao Family CCC	-	-	-	-	-	-	-	-	20	-
UC San Diego Moores CC	-	-	-	-	-	-	-	-	25	-
U Arkansas for Medical Sciences	3	-	-	-	-	-	-	-	-	-
U Colorado CC LAPS	-	-	-	-	-	-	-	-	8	-
U Kansas CC - MCA Rural MU NCORP	5	1	-	-	4	-	-	-	-	22
U Rochester LAPS	4	-	-	-	-	-	-	-	-	-
U Utah - Huntsman Cancer Inst LAPS	-	-	2	-	-	-	-	-	-	-
Upstate Carol Consort Comm Onc Res Prog	-	2	-	-	-	-	-	-	-	-
Western States Ca Res NCORP	-	1	1	-	-	-	-	-	-	-
William Beaumont Hosp-Royal Oak	-	-	-	-	-	-	-	-	2	-
Wisconsin NCORP	1	1	-	-	-	-	-	-	-	-
Yale U - Yale CC LAPS	27	-	-	-	-	-	-	-	7	-
ALLIANCE	4	4	-	-	-	-	-	-	-	-
ECOG-ACRIN	16	1	-	-	-	-	-	-	-	-
NRG	14	-	-	-	-	-	-	-	-	-
Total	228	30	36	1	4	1	1	3	165	23

